The estimated cost per quality-adjusted life year for the PCSK9 drugs is $300,000. How should health plans respond?
I am pretty sure most of the readers of The American Journal of Managed Care are earning a lot of money, but now there is a $300,000 per year opportunity (or approximately $150 per working hour) open to nearly any American…namely the cost of the benefit of taking one of the PCSK9 drugs. That is the estimated cost for an additional year of life for those taking this new class of drugs that decrease cholesterol levels at a cost of about $14,000 per year per person.
Currently, 27% of American adults have an elevated cholesterol that could potentially be the target for this class of drugs. If only 5% of these took the drug, the premium for your health insurance would rise by $124 next year. That would buy you a lot of happy meals, which, in turn, might allow you to benefit from these drugs!
Much has been written about the cost of pharmaceutical agents and health plans are lamenting the rapid rise of this drug class, but little is being done to actually get to the root causes of our national crisis—obesity, metabolic syndrome, pre-diabetes, lack of exercise, and lack of adherence to evidence-based guidelines—many of which demand the initiation of much less expensive statins to control the same problem. The CDC states that about 1 in 3 adults in the US need to be referred to intensive behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention (and I might add adherence to drugs to control the consequences of this bad behavior). The problem is, where do we find this type of counseling?
Existing programs are insufficient to perform this level of activity.
Only digital medicine offers the ability to scale to this level of need. The use of a virtual health assistant is inevitable. But when will insurers and retail pharmacies (who have publicly stated they want to be the keepers of our primary healthcare needs) step up and accept the role of protecting our collective health by incorporating effective and cutting edge cognitive technologies into their offerings?
There is a growing body of evidence that virtual assistants can significantly affect outcomes. Now is the time to start to deploy this technology.
Or perhaps you would rather have the $300,000 per year solution?
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen